Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Vanguard Group Inc.

Key Points

• Vanguard Group Inc. reduced its stake in Hologic by 0.3%, now owning approximately 26.8 million shares valued at $1.66 billion.
• Analysts have recently upgraded Hologic's stock ratings, with Citigroup raising its price target from $60 to $80, while Royal Bank of Canada increased its target from $72 to $87.
• Hologic reported quarterly earnings of $1.08 EPS, exceeding expectations, with revenues of $1.02 billion, marking a 1.2% year-over-year increase.

Vanguard Group Inc. trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 0.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,815,519 shares of the medical equipment provider's stock after selling 78,119 shares during the period. Vanguard Group Inc. owned approximately 11.95% of Hologic worth $1,656,395,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Liberty Wealth Management LLC acquired a new stake in shares of Hologic during the 1st quarter worth $660,000. J. Safra Sarasin Holding AG increased its holdings in shares of Hologic by 10.6% during the 1st quarter. J. Safra Sarasin Holding AG now owns 7,909 shares of the medical equipment provider's stock worth $489,000 after buying an additional 759 shares during the last quarter. Bank of Nova Scotia increased its holdings in shares of Hologic by 45.8% during the 1st quarter. Bank of Nova Scotia now owns 142,322 shares of the medical equipment provider's stock worth $8,791,000 after buying an additional 44,710 shares during the last quarter. R Squared Ltd purchased a new stake in Hologic during the 1st quarter worth $421,000. Finally, United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund boosted its position in Hologic by 4.1% during the 1st quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 10,100 shares of the medical equipment provider's stock worth $624,000 after purchasing an additional 400 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HOLX. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. UBS Group upped their price target on shares of Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research report on Thursday, July 31st. Evercore ISI upped their price target on shares of Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and upped their price target for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. Finally, Mizuho set a $75.00 price target on shares of Hologic in a research report on Thursday, July 31st. Ten analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Hologic has an average rating of "Moderate Buy" and a consensus target price of $77.83.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded down $0.87 during trading hours on Thursday, hitting $68.11. The stock had a trading volume of 473,170 shares, compared to its average volume of 2,792,391. The stock's fifty day simple moving average is $65.43 and its 200 day simple moving average is $62.69. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39. The firm has a market capitalization of $15.15 billion, a price-to-earnings ratio of 28.21, a PEG ratio of 2.47 and a beta of 0.49. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the business earned $1.06 earnings per share. Hologic's revenue was up 1.2% compared to the same quarter last year. Sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.